Search Results

You are looking at 21 - 30 of 1,454 items for :

  • Refine by Access: All x
Clear All
Full access

Renal Cell Cancer: A Shift in Approaches for Treatment of Advanced Disease in the United States

Matthew P. Banegas, Linda C. Harlan, Bhupinder Mann, and K. Robin Yabroff

treated for localized disease, and nearly 30% will be diagnosed with metastatic disease. 2 While surgery remains the primary treatment for localized RCC, 3 treatment options for metastatic RCC have changed markedly in the past decade. Before 2005

Full access

Modern Approaches to Localized Cancer of the Esophagus

Robert E. Glasgow, David H. Ilson, James A. Hayman, Hans Gerdes, Mary F. Mulcahy, and Jaffer A. Ajani

patients have distant metastatic disease, extraregional nodal disease, or T4b tumors (involvement of the heart, great vessels, trachea), or are unable to tolerate surgery or multimodality therapy because of insufficient functional status. Even with optimal

Full access

Modern Surgical Considerations for Gastric Cancer

Quan P. Ly and Aaron R. Sasson

. Histopathologic validation of lymph node staging with FDG-PET scan in cancer of the esophagus and gastroesophageal junction: a prospective study based on primary surgery with extensive lymphadenectomy . Ann Surg 2000 ; 232 : 743 – 752 . 9. Yun M Lim

Full access

Unanswered Questions About Margin Recommendations for Primary Cutaneous Melanoma

Joyce Y. Wong and Vernon K. Sondak

Acceptable Option for Invasive Melanoma? Mohs micrographic surgery, traditionally considered contraindicated for invasive melanomas, has been studied in melanoma in situ, particularly in cosmetically sensitive areas such as the head and neck. Using this

Full access

Indications for Minimally Invasive Surgery for Ovarian Cancer

Ernest S. Han and Mark Wakabayashi

Advanced-stage disease (stage III–IV) is diagnosed in 75% to 85% of patients, and standard management generally involves cytoreductive surgery and platinum/taxane-based chemotherapy. 2 Novel strategies and technologies are desperately needed to diagnose

Full access

Role of Laparoscopic Surgery in the Management of Endometrial Cancer

Meaghan Tenney and Joan L. Walker

Gynecologic Oncology Group study (LAP2) . J Clin Oncol 2009 ( submitted ). 22 Malur S Possover M Michels W Schneider A . Laparoscopic-assisted vaginal versus abdominal surgery in patients with endometrial cancer--a prospective randomized trial

Full access

Weekend Effect in Emergency Colon and Rectal Cancer Surgery: A Prospective Study Using Data From the Dutch ColoRectal Audit

Daniëlle D. Huijts, Julia T. van Groningen, Onno R. Guicherit, Jan Willem T. Dekker, Leti van Bodegom-Vos, Esther Bastiaannet, Johannes A. Govaert, Michel W. Wouters, and Perla J. Marang-van de Mheen

Background Colorectal cancer (CRC) is a frequently diagnosed cancer for which surgery has a crucial role in treatment. Unfortunately, surgery also carries considerable risks of postoperative complications and mortality. 1 , 2 There are

Full access

Race of the Clock: Reducing Delay to Curative Breast Cancer Surgery

Loretta Loftus, Christine Laronga, Karen Coyne, and Lynne Hildreth

among sponsored institutions was provided. Analysis of the NCCN TiCToC (Timing in Continuation and Transition of Care) Measures revealed that Moffitt Cancer Center lagged in the time from breast biopsy to first definitive surgery with an average of 6

Full access

Expanding the Use of Nephron-Sparing Surgery for Wilms Tumor

Christopher J. Long, Sameer Mittal, and Thomas F. Kolon

intrinsic renal disease are thought to contribute to the eventual development of renal failure in some patients, the loss of renal mass from tumor resection is also a potential factor. 2 Current Indications for Partial Nephrectomy Nephron-sparing surgery

Full access

Factors Associated With Delays in Chemotherapy Initiation Among Patients With Breast Cancer at a Comprehensive Cancer Center

Katya Losk, Ines Vaz-Luis, Kristen Camuso, Rafael Batista, Max Lloyd, Mustafa Tukenmez, Mehra Golshan, Nancy U. Lin, and Craig A. Bunnell

delays in adjuvant chemotherapy initiation greater than 49 to 90 days after surgery may be associated with inferior outcomes, particularly among patients with triple-negative breast cancer (TNBC), HER2-positive subtypes, and higher-stage tumors. 7 – 12 A